CHINA MEDICAL SYSTEM HOLDINGS LIMITED ANNUAL REPORT 2025
Units appear below each metric. Scroll to compare years
| Metric / unit | 2025Group | 2024Group | Source |
|---|---|---|---|
| Profit or loss | |||
| RevenueRMB'000 | 8,212,058 | 7,468,990 | PDF p. 82 |
| Cost of goods soldRMB'000 | (2,340,522) | (2,046,796) | PDF p. 82 |
| Gross profitRMB'000 | 5,871,536 | 5,422,194 | PDF p. 82 |
| Other incomeRMB'000 | 145,672 | 208,387 | PDF p. 82 |
| Other gains and lossesRMB'000 | 156,907 | (151,244) | PDF p. 82 |
| Selling expensesRMB'000 | (2,842,252) | (2,661,648) | PDF p. 82 |
| Administrative expensesRMB'000 | (865,777) | (780,093) | PDF p. 82 |
| Finance costsRMB'000 | (20,297) | (38,610) | PDF p. 82 |
| Research and development expensesRMB'000 | (585,023) | (329,982) | PDF p. 82 |
| Share of results of associatesRMB'000 | 238,790 | 338,548 | PDF p. 82 |
| Share of result of a joint ventureRMB'000 | 3,505 | 2,755 | PDF p. 82 |
| Profit before taxRMB'000 | 2,103,061 | 2,010,307 | PDF p. 82 |
| Income tax expenseRMB'000 | (659,784) | (397,227) | PDF p. 82 |
| Profit for the yearRMB'000 | 1,443,277 | 1,613,080 | PDF p. 82 |
| Other comprehensive income | |||
| Fair value gain (loss) on investments in equity instruments at fair value through other comprehensive incomeRMB'000 | 227,810 | (34,110) | PDF p. 82 |
| Share of other comprehensive (expense) income of associatesRMB'000 | (6,568) | 6,162 | PDF p. 82 |
| Exchange differences arising on translation of foreign operationsRMB'000 | (8,284) | 3,038 | PDF p. 82 |
| Exchange differences arising on translation of interests in associatesRMB'000 | 15,664 | (9,061) | PDF p. 82 |
| Other comprehensive income (expense) for the year, net of income taxRMB'000 | 228,622 | (33,971) | PDF p. 82 |
| Total comprehensive income | |||
| Total comprehensive income for the yearRMB'000 | 1,671,899 | 1,579,109 | PDF p. 82 |
| Profit (loss) for the year attributable to | |||
| Owners of the CompanyRMB'000 | 1,488,892 | 1,619,788 | PDF p. 82 |
| Non-controlling interestsRMB'000 | (45,615) | (6,708) | PDF p. 82 |
| SubtotalRMB'000 | 1,443,277 | 1,613,080 | PDF p. 82 |
| Total comprehensive income (expense) for the year attributable to | |||
| Owners of the CompanyRMB'000 | 1,717,514 | 1,585,817 | PDF p. 82 |
| Non-controlling interestsRMB'000 | (45,615) | (6,708) | PDF p. 82 |
| SubtotalRMB'000 | 1,671,899 | 1,579,109 | PDF p. 82 |
| Earnings per share | |||
| BasicRMB per share | 0.6154 | 0.6673 | PDF p. 82 |
Original report: PDF p. 82 ↗
Only basic EPS printed. Notes column references omitted from values.
Units appear below each metric. Scroll to compare years
| Metric / unit | 2025Group | 2024Group | Source |
|---|---|---|---|
| Non-current assets | |||
| Property, plant and equipmentRMB'000 | 366,702 | 375,893 | PDF p. 83 |
| Right-of-use assetsRMB'000 | 79,388 | 72,197 | PDF p. 83 |
| Interests in associatesRMB'000 | 3,509,594 | 3,389,827 | PDF p. 83 |
| Interest in a joint ventureRMB'000 | 172,308 | 181,804 | PDF p. 83 |
| Intangible assetsRMB'000 | 2,213,765 | 2,301,346 | PDF p. 83 |
| GoodwillRMB'000 | 1,511,261 | 1,547,903 | PDF p. 83 |
| Equity instruments at fair value through other comprehensive incomeRMB'000 | 357,593 | 129,783 | PDF p. 83 |
| Deposits paid for acquisition of intangible assetsRMB'000 | 1,480,664 | 1,189,256 | PDF p. 83 |
| Amounts due from associatesRMB'000 | 30,000 | 30,000 | PDF p. 83 |
| Deferred tax assetsRMB'000 | 58,795 | 52,693 | PDF p. 83 |
| Loan receivableRMB'000 | 120,216 | 72,227 | PDF p. 83 |
| SubtotalRMB'000 | 9,900,286 | 9,342,929 | PDF p. 83 |
| Current assets | |||
| InventoriesRMB'000 | 803,958 | 768,139 | PDF p. 83 |
| Financial assets at fair value through profit or lossRMB'000 | 3,084,902 | 2,160,097 | PDF p. 83 |
| Trade and other receivables and prepaymentsRMB'000 | 2,258,566 | 1,780,483 | PDF p. 83 |
| Tax recoverableRMB'000 | 1,270 | 5,553 | PDF p. 83 |
| Amounts due from associatesRMB'000 | 448,493 | 284,088 | PDF p. 83 |
| Bank balances and cashRMB'000 | 2,701,380 | 3,706,501 | PDF p. 83 |
| SubtotalRMB'000 | 9,298,569 | 8,704,861 | PDF p. 83 |
| Current liabilities | |||
| Trade and other payablesRMB'000 | 495,716 | 484,797 | PDF p. 83 |
| Lease liabilitiesRMB'000 | 16,597 | 16,933 | PDF p. 83 |
| Contract liabilitiesRMB'000 | 12,133 | 16,610 | PDF p. 83 |
| Bank borrowingsRMB'000 | 651,815 | 831,300 | PDF p. 83 |
| Tax liabilitiesRMB'000 | 292,962 | 166,423 | PDF p. 83 |
| SubtotalRMB'000 | 1,469,223 | 1,516,063 | PDF p. 83 |
| Net current assets | |||
| Net current assetsRMB'000 | 7,829,346 | 7,188,798 | PDF p. 83 |
| Total assets less current liabilitiesRMB'000 | 17,729,632 | 16,531,727 | PDF p. 83 |
| Capital and reserves | |||
| Share capitalRMB'000 | 83,564 | 83,564 | PDF p. 84 |
| ReservesRMB'000 | 17,312,174 | 16,227,905 | PDF p. 84 |
| Equity attributable to owners of the CompanyRMB'000 | 17,395,738 | 16,311,469 | PDF p. 84 |
| Non-controlling interestsRMB'000 | 147,025 | 91,639 | PDF p. 84 |
| SubtotalRMB'000 | 17,542,763 | 16,403,108 | PDF p. 84 |
| Non-current liabilities | |||
| Deferred tax liabilitiesRMB'000 | 165,202 | 116,109 | PDF p. 84 |
| Lease liabilitiesRMB'000 | 21,667 | 12,510 | PDF p. 84 |
| SubtotalRMB'000 | 186,869 | 128,619 | PDF p. 84 |
| Total (net assets funded) | |||
| SubtotalRMB'000 | 17,729,632 | 16,531,727 | PDF p. 84 |
Original report: PDF p. 83 ↗ PDF p. 84 ↗
Statement spans physical pages 83-84; table header repeated on page 84.
Units appear below each metric. Scroll to compare years
| Metric / unit | 2025Group, year ended 31 Dec 2025, RMB'000 | 2024Group, year ended 31 Dec 2024, RMB'000 | Source |
|---|---|---|---|
| Profit or loss | |||
| Profit before taxRMB'000 | 2,103,061 | 2,010,307 | PDF p. 82 |
| Income tax expenseRMB'000 | (659,784) | (397,227) | PDF p. 82 |
| Profit for the yearRMB'000 | 1,443,277 | 1,613,080 | PDF p. 82 |
| Other comprehensive income - not reclassified | |||
| Fair value gain (loss) on investments in equity instruments at fair value through other comprehensive incomeRMB'000 | 227,810 | (34,110) | PDF p. 82 |
| Other comprehensive income - may be reclassified | |||
| Share of other comprehensive (expense) income of associatesRMB'000 | (6,568) | 6,162 | PDF p. 82 |
| Exchange differences arising on translation of foreign operationsRMB'000 | (8,284) | 3,038 | PDF p. 82 |
| Exchange differences arising on translation of interests in associatesRMB'000 | 15,664 | (9,061) | PDF p. 82 |
| Other comprehensive income | |||
| Other comprehensive income (expense) for the year, net of income taxRMB'000 | 228,622 | (33,971) | PDF p. 82 |
| Total comprehensive income | |||
| Total comprehensive income for the yearRMB'000 | 1,671,899 | 1,579,109 | PDF p. 82 |
| Profit (loss) for the year attributable to | |||
| Owners of the CompanyRMB'000 | 1,488,892 | 1,619,788 | PDF p. 82 |
| Non-controlling interestsRMB'000 | (45,615) | (6,708) | PDF p. 82 |
| Total comprehensive income (expense) attributable to | |||
| Owners of the CompanyRMB'000 | 1,717,514 | 1,585,817 | PDF p. 82 |
| Non-controlling interestsRMB'000 | (45,615) | (6,708) | PDF p. 82 |
| Earnings per share | |||
| BasicRMB | 0.6154 | 0.6673 | PDF p. 82 |
Original report: PDF p. 82 ↗
Earnings per share in RMB. Statement is for the Group only; no separate company-level statement printed on this page.
Units appear below each metric. Scroll to compare years
| Metric / unit | 2025Group, year ended 31 Dec 2025, RMB'000 | 2024Group, year ended 31 Dec 2024, RMB'000 | Source |
|---|---|---|---|
| Operating activities | |||
| Profit before taxRMB'000 | 2,103,061 | 2,010,307 | PDF p. 86 |
| Operating activities - adjustments | |||
| Amortisation of intangible assetsRMB'000 | 199,101 | 184,983 | PDF p. 86 |
| Impairment loss on interest in an associateRMB'000 | 20,000 | 100,000 | PDF p. 86 |
| Write-down of inventoriesRMB'000 | 20,000 | - | PDF p. 86 |
| Impairment loss recognised (reversed) on financial assets under expected credit loss model, net of reversalRMB'000 | 1,723 | (499) | PDF p. 86 |
| Impairment loss on deposit paid for acquisition of intangible assetsRMB'000 | 31,740 | 1,152 | PDF p. 86 |
| Interest expensesRMB'000 | 20,297 | 38,610 | PDF p. 86 |
| Share-based payment expenseRMB'000 | 27,310 | - | PDF p. 86 |
| Depreciation of property, plant and equipmentRMB'000 | 47,236 | 50,755 | PDF p. 86 |
| Depreciation of right-of-use assetsRMB'000 | 20,591 | 23,500 | PDF p. 86 |
| Loss (gain) on disposal of property, plant and equipmentRMB'000 | 867 | (500) | PDF p. 86 |
| Share of results of associatesRMB'000 | (238,790) | (338,548) | PDF p. 86 |
| Share of result of a joint ventureRMB'000 | (3,505) | (2,755) | PDF p. 86 |
| Interest incomeRMB'000 | (82,348) | (126,344) | PDF p. 86 |
| Dividends from financial assets at fair value through profit or lossRMB'000 | (32,068) | (1,716) | PDF p. 86 |
| Net foreign exchange lossRMB'000 | 5,110 | 4,500 | PDF p. 86 |
| Change in fair value of derivative financial instrumentsRMB'000 | - | (17,227) | PDF p. 86 |
| Change in fair value of financial assets at fair value through profit or lossRMB'000 | (230,987) | 9,025 | PDF p. 86 |
| Gain on disposal of a subsidiaryRMB'000 | (19,594) | - | PDF p. 86 |
| Operating activities | |||
| Operating cash flows before movements in working capitalRMB'000 | 1,889,744 | 1,935,243 | PDF p. 86 |
| Operating activities - working capital | |||
| Increase in inventoriesRMB'000 | (55,905) | (130,503) | PDF p. 86 |
| Increase in trade and other receivables and prepaymentsRMB'000 | (446,763) | (173,422) | PDF p. 86 |
| (Increase) decrease in amounts due from associatesRMB'000 | (164,405) | 124,079 | PDF p. 86 |
| Increase in trade and other payablesRMB'000 | 22,768 | 47,821 | PDF p. 86 |
| (Decrease) increase in contract liabilitiesRMB'000 | (4,477) | 3,877 | PDF p. 86 |
| Operating activities | |||
| Cash generated from operationsRMB'000 | 1,240,962 | 1,807,095 | PDF p. 87 |
| People’s Republic of China (the “PRC”) Enterprise Income Tax paidRMB'000 | (427,426) | (386,506) | PDF p. 87 |
| Hong Kong Profits Tax paidRMB'000 | (1,301) | (79,100) | PDF p. 87 |
| Macau Complementary Income Tax paidRMB'000 | (40,356) | (72,942) | PDF p. 87 |
| Income tax payments in other countriesRMB'000 | (13,458) | - | PDF p. 87 |
| Net cash from operating activitiesRMB'000 | 758,421 | 1,268,547 | PDF p. 87 |
| Investing activities | |||
| Interest receivedRMB'000 | 82,348 | 126,344 | PDF p. 87 |
| Dividend received from an associateRMB'000 | 225,276 | 184,691 | PDF p. 87 |
| Dividend received from a joint ventureRMB'000 | 13,001 | - | PDF p. 87 |
| Dividends received from financial assets at fair value through profit or lossRMB'000 | 32,068 | 1,716 | PDF p. 87 |
| Purchase of property, plant and equipmentRMB'000 | (41,037) | (32,619) | PDF p. 87 |
| Proceeds from disposal of property, plant and equipmentRMB'000 | 1,369 | 4,087 | PDF p. 87 |
| Disposal of financial assets at fair value through profit or lossRMB'000 | 14,478 | 6,007 | PDF p. 87 |
| Purchase of financial assets at fair value through profit or lossRMB'000 | (708,296) | (342,871) | PDF p. 87 |
| Purchase of intangible assetsRMB'000 | - | (114,674) | PDF p. 87 |
| Proceeds on disposal of an interest in an associateRMB'000 | 8,008 | - | PDF p. 87 |
| Deposits paid for acquisition of intangible assetsRMB'000 | (473,374) | (308,615) | PDF p. 87 |
| Capital injection to associatesRMB'000 | (125,165) | (66,935) | PDF p. 87 |
| Net cash inflow on disposal of a subsidiaryRMB'000 | 34,991 | - | PDF p. 87 |
| Loan to third partiesRMB'000 | (47,989) | (72,227) | PDF p. 87 |
| NET CASH USED IN INVESTING ACTIVITIESRMB'000 | (984,322) | (615,096) | PDF p. 87 |
| Financing activities | |||
| New bank borrowings raisedRMB'000 | 682,515 | 831,300 | PDF p. 88 |
| Repayment for deferred consideration payableRMB'000 | - | (1,000) | PDF p. 88 |
| Interest paidRMB'000 | (20,297) | (38,610) | PDF p. 88 |
| Dividends paidRMB'000 | (660,555) | (556,162) | PDF p. 88 |
| Repayment of bank borrowingsRMB'000 | (862,000) | (1,274,150) | PDF p. 88 |
| Repayments of lease liabilitiesRMB'000 | (18,961) | (22,217) | PDF p. 88 |
| Payment on repurchase of sharesRMB'000 | - | (238,394) | PDF p. 88 |
| Capital contribution from non-controlling interestsRMB'000 | 108,362 | 38,187 | PDF p. 88 |
| NET CASH USED IN FINANCING ACTIVITIESRMB'000 | (770,936) | (1,261,046) | PDF p. 88 |
| Net change in cash | |||
| NET DECREASE IN CASH AND CASH EQUIVALENTSRMB'000 | (996,837) | (607,595) | PDF p. 88 |
| CASH AND CASH EQUIVALENT AT THE BEGINNING OF YEARRMB'000 | 3,706,501 | 4,311,058 | PDF p. 88 |
| Effects of exchange rate changes on the balance of cash held in foreign currenciesRMB'000 | (8,284) | 3,038 | PDF p. 88 |
| Closing cash | |||
| CASH AND CASH EQUIVALENT AT THE END OF YEAR REPRESENTED BY BANK BALANCES AND CASHRMB'000 | 2,701,380 | 3,706,501 | PDF p. 88 |
Original report: PDF p. 86 ↗ PDF p. 87 ↗ PDF p. 88 ↗
Spans physical pages 86-88; page 88 is headed 'Consolidated statement of financial position (continued)' but contains the financing section.
Units appear below each metric. Scroll to compare years
| Metric / unit | 2025Share capital, RMB'000 | 2025Share premium, RMB'000 | 2025Capital reserve (Note 32), RMB'000 | 2025Surplus reserve fund (Note 32), RMB'000 | 2025Translation reserve, RMB'000 | 2025Investments revaluation reserve, RMB'000 | 2025Accumulated profits, RMB'000 | 2025Dividend reserve, RMB'000 | 2025Treasury Stock, RMB'000 | 2025Sub-total attributable to owners of the Company, RMB'000 | 2025Attributable to non-controlling interests, RMB'000 | 2025Total, RMB'000 | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening 2024 | |||||||||||||
| Balance at 1 January 2024RMB'000 | 83,991 | 2,105,621 | 19,545 | 425,635 | 65,052 | (371,956) | 13,000,329 | 191,991 | - | 15,520,208 | 36,199 | 15,556,407 | PDF p. 85 |
| Year 2024 | |||||||||||||
| Profit (loss) for the yearRMB'000 | - | - | - | - | - | - | 1,619,788 | - | - | 1,619,788 | (6,708) | 1,613,080 | PDF p. 85 |
| Share of other comprehensive income of associatesRMB'000 | - | - | - | - | 6,162 | - | - | - | - | 6,162 | - | 6,162 | PDF p. 85 |
| Exchange differences arising on translation of foreign operationsRMB'000 | - | - | - | - | 3,038 | - | - | - | - | 3,038 | - | 3,038 | PDF p. 85 |
| Exchange differences arising on translation of interests in associatesRMB'000 | - | - | - | - | (9,061) | - | - | - | - | (9,061) | - | (9,061) | PDF p. 85 |
| Fair value loss on investments in equity instruments at fair value through other comprehensive incomeRMB'000 | - | - | - | - | - | (34,110) | - | - | - | (34,110) | - | (34,110) | PDF p. 85 |
| Total comprehensive income (expense) for the yearRMB'000 | - | - | - | - | 139 | (34,110) | 1,619,788 | - | - | 1,585,817 | (6,708) | 1,579,109 | PDF p. 85 |
| Repurchase of ordinary shares in treasury stock (Note 31)RMB'000 | - | - | - | - | - | - | - | - | (238,394) | (238,394) | - | (238,394) | PDF p. 85 |
| Cancellation of ordinary shares (Note 31)RMB'000 | (427) | (80,020) | - | - | - | - | - | - | 80,447 | - | - | - | PDF p. 85 |
| Capital contribution from non-controlling interestsRMB'000 | - | - | - | - | - | - | - | - | - | - | 62,148 | 62,148 | PDF p. 85 |
| Dividends paid (Note 13)RMB'000 | - | - | - | - | - | - | (364,171) | (191,991) | - | (556,162) | - | (556,162) | PDF p. 85 |
| Dividends proposed (Note 13)RMB'000 | - | - | - | - | - | - | (283,700) | 283,700 | - | - | - | - | PDF p. 85 |
| Transfer of reservesRMB'000 | - | - | - | 13,237 | - | - | (13,237) | - | - | - | - | - | PDF p. 85 |
| Closing 2024 / opening 2025 | |||||||||||||
| Balance at 31 December 2024RMB'000 | 83,564 | 2,025,601 | 19,545 | 438,872 | 65,191 | (406,066) | 13,959,009 | 283,700 | (157,947) | 16,311,469 | 91,639 | 16,403,108 | PDF p. 85 |
| Year 2025 | |||||||||||||
| Profit (loss) for the yearRMB'000 | - | - | - | - | - | - | 1,488,892 | - | - | 1,488,892 | (45,615) | 1,443,277 | PDF p. 85 |
| Exchange differences arising on translation of foreign operationsRMB'000 | - | - | - | - | (8,284) | - | - | - | - | (8,284) | - | (8,284) | PDF p. 85 |
| Exchange differences arising on translation of interests in associatesRMB'000 | - | - | - | - | 15,664 | - | - | - | - | 15,664 | - | 15,664 | PDF p. 85 |
| Fair value gain on investments in equity instruments at fair value through other comprehensive incomeRMB'000 | - | - | - | - | - | 227,810 | - | - | - | 227,810 | - | 227,810 | PDF p. 85 |
| Total comprehensive income (expense) for the yearRMB'000 | - | - | - | - | 812 | 227,810 | 1,488,892 | - | - | 1,717,514 | (45,615) | 1,671,899 | PDF p. 85 |
| Distribution of treasury stock to employees (Note 31)RMB'000 | - | 24 | - | - | - | - | - | - | 27,286 | 27,310 | - | 27,310 | PDF p. 85 |
| Capital contribution from non-controlling interestsRMB'000 | - | - | - | - | - | - | - | - | - | - | 108,362 | 108,362 | PDF p. 85 |
| Dividends paid (Note 13)RMB'000 | - | - | - | - | - | - | (376,855) | (283,700) | - | (660,555) | - | (660,555) | PDF p. 85 |
| Dividends proposed (Note 13)RMB'000 | - | - | - | - | - | - | (330,641) | 330,641 | - | - | - | - | PDF p. 85 |
| Disposal of a subsidiary( Note 40)RMB'000 | - | - | - | - | - | - | - | - | - | - | (7,361) | (7,361) | PDF p. 85 |
| Transfer of reservesRMB'000 | - | - | - | 1,684 | - | - | (1,684) | - | - | - | - | - | PDF p. 85 |
| Closing 2025 | |||||||||||||
| Balance at 31 December 2025RMB'000 | 83,564 | 2,025,625 | 19,545 | 440,556 | 66,003 | (178,256) | 14,738,721 | 330,641 | (130,661) | 17,395,738 | 147,025 | 17,542,763 | PDF p. 85 |
Original report: PDF p. 85 ↗
Rows cover movements from 1 January 2024 to 31 December 2025 as printed; each row's date/period is in its label. No separate Company-level statement of changes in equity was on the page read.
Units appear below each metric. Scroll to compare years
| Metric / unit | 2021Group, as at 31 December, RMB'000 | 2022Group, as at 31 December, RMB'000 | 2023Group, as at 31 December, RMB'000 | 2024Group, as at 31 December, RMB'000 | 2025Group, as at 31 December, RMB'000 | Source |
|---|---|---|---|---|---|---|
| Summary of Consolidated Statement of Financial Position | ||||||
| Total assetsRMB'000 | 15,807,879 | 17,753,539 | 17,730,837 | 18,047,790 | 19,198,855 | PDF p. 4 |
| Total liabilitiesRMB'000 | 2,960,892 | 3,016,462 | 2,174,430 | 1,644,682 | 1,656,092 | PDF p. 4 |
| Net assetsRMB'000 | 12,846,987 | 14,737,077 | 15,556,407 | 16,403,108 | 17,542,763 | PDF p. 4 |
Original report: PDF p. 4 ↗
Only the balance sheet summary spans five years; no five-year income or cash flow summary is printed.
Units appear below each metric. Scroll to compare years
| Metric / unit | 2025Group, year ended 31 December 2025, RMB (million unless stated) | 2024Group, year ended 31 December 2024, comparative, RMB (million unless stated) | Source |
|---|---|---|---|
| Financial Highlights | |||
| TurnoverRMB million | 8,212.1 | 7,469.0 | PDF p. 4 |
| Turnover (in the case that all medicines were directly sold by the Group)RMB million | 9,385.6 | 8,621.6 | PDF p. 4 |
| Gross profitRMB million | 5,871.5 | 5,422.2 | PDF p. 4 |
| Gross profit (in the case that all medicines were directly sold by the Group)RMB million | 5,852.0 | 5,405.4 | PDF p. 4 |
| Profit for the yearRMB million | 1,443.3 | 1,613.1 | PDF p. 4 |
| Normalized profit for the year*RMB million | 1,775.5 | 1,713.7 | PDF p. 4 |
| Basic earnings per shareRMB per share | 0.6154 | 0.6673 | PDF p. 4 |
| Total dividend for the yearRMB per share | 0.2921 | 0.2681 | PDF p. 4 |
Original report: PDF p. 4 ↗
* Normalized profit for the year of 2025 mainly refers to excluding a one-off payment of RMB278.8 million, consisting of the repayment of the local income tax concession enjoyed for the years from 2022 to 2024 and the related late payment surcharge.
Bank balances and cash printed only for 31 December 2025 in this bullet; 2024 value (RMB3,706.5 million) appears in MD&A. 2024 total dividend 0.2681 and final 0.1174 are from the same bullet.
Units appear below each metric. Scroll to compare years
| Metric / unit | 2025Group, year ended 31 December 2025, RMB'000 | 2024Group, year ended 31 December 2024, RMB'000 | Source |
|---|---|---|---|
| Management Discussion and Analysis - cash flow summary | |||
| Net cash from operating activitiesRMB'000 | 758,421 | 1,268,547 | PDF p. 42 |
| Net cash used in investing activitiesRMB'000 | (984,322) | (615,096) | PDF p. 42 |
| Net cash used in financing activitiesRMB'000 | (770,936) | (1,261,046) | PDF p. 42 |
| Net decrease in cash and cash equivalentRMB'000 | (996,837) | (607,595) | PDF p. 42 |
| Cash and cash equivalent at beginning of the yearRMB'000 | 3,706,501 | 4,311,058 | PDF p. 42 |
| Effect of foreign exchange rate changesRMB'000 | (8,284) | 3,038 | PDF p. 42 |
| Cash and cash equivalent at end of the yearRMB'000 | 2,701,380 | 3,706,501 | PDF p. 42 |
Original report: PDF p. 42 ↗
Units appear below each metric. Scroll to compare years
| Metric / unit | 2025Group, as at 31 December 2025, RMB'000 | 2024Group, as at 31 December 2024, RMB'000 | Source |
|---|---|---|---|
| Current Assets | |||
| InventoriesRMB'000 | 803,958 | 768,139 | PDF p. 43 |
| Financial assets at fair value through profit or lossRMB'000 | 3,084,902 | 2,160,097 | PDF p. 43 |
| Trade receivablesRMB'000 | 1,587,874 | 1,222,479 | PDF p. 43 |
| Other receivables and prepaymentsRMB'000 | 670,692 | 558,004 | PDF p. 43 |
| Tax recoverableRMB'000 | 1,270 | 5,553 | PDF p. 43 |
| Amount due from associatesRMB'000 | 448,493 | 284,088 | PDF p. 43 |
| Bank balances and cashRMB'000 | 2,701,380 | 3,706,501 | PDF p. 43 |
| Current Liabilities | |||
| Trade payablesRMB'000 | 106,575 | 142,432 | PDF p. 43 |
| Other payablesRMB'000 | 389,141 | 342,365 | PDF p. 43 |
| Lease liabilitiesRMB'000 | 16,597 | 16,933 | PDF p. 43 |
| Contract liabilitiesRMB'000 | 12,133 | 16,610 | PDF p. 43 |
| Bank borrowingsRMB'000 | 651,815 | 831,300 | PDF p. 43 |
| Tax liabilitiesRMB'000 | 292,962 | 166,423 | PDF p. 43 |
| Net Current Assets | |||
| Net current assetsRMB'000 | 7,829,346 | 7,188,798 | PDF p. 43 |
Original report: PDF p. 43 ↗
Subtotals for current assets (9,298,569 / 8,704,861) and current liabilities (1,469,223 / 1,516,063) are printed unlabelled and not extracted as rows.
Units appear below each metric. Scroll to compare years
| Metric / unit | 2025Group, year ended / as at 31 December 2025, RMB'000 | 2024Group, year ended / as at 31 December 2024, RMB'000 | Source |
|---|---|---|---|
| Capital Expenditures | |||
| Deposits for acquisition of intangible assetsRMB'000 | 473,374 | 423,289 | PDF p. 43 |
| Purchase of property, plant and equipmentRMB'000 | 41,037 | 32,619 | PDF p. 43 |
| Capital Structure and Gearing Ratio | |||
| Interest bearing bank borrowingsRMB'000 | 651,815 | 831,300 | PDF p. 43 |
Original report: PDF p. 43 ↗
Total capital expenditure 514,411 / 455,908 printed unlabelled.
Units appear below each metric. Scroll to compare years
| Metric / unit | 2025Group, 2025 (or as at 31 December 2025) | 2024Group, 2024 (or as at 31 December 2024) | Source |
|---|---|---|---|
| Capital Structure and Gearing Ratio | |||
| Gearing ratio, calculated as bank borrowings divided by total assets% | 3.4 | 4.6 | PDF p. 44 |
| Gross Profit and Gross Profit Margin | |||
| Gross profit margin% | 71.5 | 72.6 | PDF p. 39 |
| Gross profit margin (in the case that all medicines were directly sold by the Group)% | 62.4 | 62.7 | PDF p. 39 |
| Inventories | |||
| Average inventory turnover daysdays | 123 | 125 | PDF p. 41 |
| Trade Receivables | |||
| Average trade receivables turnover daysdays | 79 | 75 | PDF p. 41 |
| Trade Payables | |||
| Average trade payables turnover daysdays | 19 | 25 | PDF p. 41 |
Original report: PDF p. 44 ↗ PDF p. 39 ↗ PDF p. 41 ↗
Gearing ratio defined as bank borrowings divided by total assets.
Units appear below each metric. Scroll to compare years
| Metric / unit | 2025Group, year ended 31 December 2025 | 2024Group, year ended 31 December 2024 | Source |
|---|---|---|---|
| Number of shares | |||
| Weighted average number of ordinary shares for the purpose of basic earnings per sharenumber of shares | 2,419,522,170 | 2,427,382,419 | PDF p. 125 |
Original report: PDF p. 125 ↗
No diluted earnings per share for both 2025 and 2024 were presented as there were no potential ordinary shares in issue for both 2025 and 2024.
Basic EPS RMB0.6154 (2025) and RMB0.6673 (2024) per page 4 highlights.
Where the money comes from
| Item / unit | 2025Integrated Business, RMB'000 | 2025Skin Health Business, RMB'000 | 2025Elimination, RMB'000 | 2025Total, RMB'000 | Source |
|---|---|---|---|---|---|
| Segment information | |||||
| External revenueRMB'000 | 7,146,828 | 1,065,230 | - | 8,212,058 | PDF p. 115 |
| Inter-segment revenueRMB'000 | 27,980 | 4,619 | (32,599) | - | PDF p. 115 |
| TurnoverRMB'000 | 7,174,808 | 1,069,849 | (32,599) | 8,212,058 | PDF p. 115 |
| Gross profitRMB'000 | 5,223,110 | 674,415 | (25,989) | 5,871,536 | PDF p. 115 |
| Segment profit (loss) for the yearRMB'000 | 1,546,972 | (103,695) | - | 1,443,277 | PDF p. 115 |
Group reorganised reporting into two segments (Integrated Business and Skin Health Business); prior year segment disclosures represented.
| Item / unit | 2024Integrated Business, RMB'000 | 2024Skin Health Business, RMB'000 | 2024Elimination, RMB'000 | 2024Total, RMB'000 | Source |
|---|---|---|---|---|---|
| Segment information | |||||
| External revenueRMB'000 | 6,899,028 | 569,962 | - | 7,468,990 | PDF p. 116 |
| Inter-segment revenueRMB'000 | 62,544 | 47,568 | (110,112) | - | PDF p. 116 |
| TurnoverRMB'000 | 6,961,572 | 617,530 | (110,112) | 7,468,990 | PDF p. 116 |
| Gross profitRMB'000 | 5,080,862 | 391,860 | (50,528) | 5,422,194 | PDF p. 116 |
| Segment profit (loss) for the yearRMB'000 | 1,747,140 | (105,630) | (28,430) | 1,613,080 | PDF p. 116 |
Prior year segment disclosures have been represented to conform with current presentation.
| Item / unit | 2025Integrated Business, RMB'000 | 2025Skin Health Business, RMB'000 | 2025Elimination, RMB'000 | 2025Total, RMB'000 | 2024Integrated Business, RMB'000 | 2024Skin Health Business, RMB'000 | 2024Elimination, RMB'000 | 2024Total, RMB'000 | Source |
|---|---|---|---|---|---|---|---|---|---|
| Segment assets and liabilities | |||||||||
| Segment assetsRMB'000 | 19,468,422 | 2,635,017 | (2,904,584) | 19,198,855 | 18,521,257 | 2,175,853 | (2,649,320) | 18,047,790 | PDF p. 116 |
| Segment liabilitiesRMB'000 | 1,554,224 | 110,151 | (8,283) | 1,656,092 | 1,653,722 | 224,825 | (233,865) | 1,644,682 | PDF p. 116 |
| Item / unit | 2025RMB'000 | 2024RMB'000 | Source |
|---|---|---|---|
| Disaggregation of revenue from contracts with customers | |||
| Sales of pharmaceutical productsRMB'000 | 6,605,238 | 5,887,214 | PDF p. 115 |
| Promotion incomeRMB'000 | 1,606,820 | 1,581,776 | PDF p. 115 |
| Total revenueRMB'000 | 8,212,058 | 7,468,990 | PDF p. 115 |
Debt
| Item / unit | 2025RMB'000 | 2024RMB'000 | Source |
|---|---|---|---|
| Bank borrowings | |||
| Bank loansRMB'000 | 651,815 | 831,300 | PDF p. 153 |
| Analysed as | |||
| UnsecuredRMB'000 | 650,033 | 831,300 | PDF p. 153 |
| SecuredRMB'000 | 1,782 | - | PDF p. 153 |
| Carrying amounts repayable | |||
| Within one yearRMB'000 | 651,815 | 831,300 | PDF p. 153 |
| Less: Amounts due within one year shown under current liabilitiesRMB'000 | (651,815) | (831,300) | PDF p. 153 |
| Amounts shown under non-current liabilitiesRMB'000 | - | - | PDF p. 153 |
* The amounts due are based on scheduled repayment dates set out in the loan agreements.
As at 31 December 2025, the Group had unutilised banking facilities of approximately RMB 3,895,427,000 (2024: RMB1,880,341,000). And approximately RMB 1,782,000 (2024: Nil) borrowings secured by land, property, plant and equipment.
| Item / unit | 2025as at 31 December 2025: weighted average interest rate % | 2025repayable on demand or less than 1 year, RMB'000 | 20251 to 5 years, RMB'000 | 2025total undiscounted cash flows, RMB'000 | 2025carrying amount at 31 December 2025, RMB'000 | Source |
|---|---|---|---|---|---|---|
| Non-derivative financial liabilities | ||||||
| Fixed-rate bank borrowings% / RMB'000 | 2.12 | 665,611 | - | 665,611 | 651,815 | PDF p. 166 |
| Lease liabilities% / RMB'000 | 4.75 | 17,385 | 24,505 | 41,890 | 38,264 | PDF p. 166 |
Table includes both interest and principal cash flows; based on undiscounted cash flows on the earliest date the Group can be required to pay.
| Item / unit | 2024weighted average interest rate % | 2024repayable on demand or less than 1 year, RMB'000 | 20241 to 5 years, RMB'000 | 2024total undiscounted cash flows, RMB'000 | 2024carrying amount at 31 December 2024, RMB'000 | Source |
|---|---|---|---|---|---|---|
| Non-derivative financial liabilities | ||||||
| Fixed-rate bank borrowings% / RMB'000 | 2.39 | 851,202 | - | 851,202 | 831,300 | PDF p. 167 |
| Lease liabilities% / RMB'000 | 4.75 | 17,737 | 13,727 | 31,464 | 29,443 | PDF p. 167 |
Table includes both interest and principal cash flows.
| Item / unit | 2025RMB'000 | 2024RMB'000 | Source |
|---|---|---|---|
| Fixed-rate borrowing | |||
| Denominated in RMB at fixed rate of 1.00% per annum as at 31 December 2025RMB'000 | 8,000 | - | PDF p. 153 |
| Denominated in RMB at fixed rate of 1.10% per annum as at 31 December 2024RMB'000 | - | 40,300 | PDF p. 153 |
| Denominated in RMB at fixed rate of 1.35% per annum as at 31 December 2024RMB'000 | - | 19,000 | PDF p. 153 |
| Denominated in RMB at fixed rate of 1.90% per annum as at 31 December 2025RMB'000 | 360,000 | - | PDF p. 153 |
| Denominated in RMB at fixed rate of 2.40% per annum as at 31 December 2025 and 2024RMB'000 | 270,000 | 185,000 | PDF p. 153 |
| Denominated in RMB at fixed rate of 2.50% per annum as at 31 December 2025 and 2024RMB'000 | 5,000 | 500,000 | PDF p. 153 |
| Denominated in RMB at fixed rate of 2.51% per annum as at 31 December 2025RMB'000 | 1,782 | - | PDF p. 153 |
| Denominated in RMB at fixed rate of 2.60% per annum as at 31 December 2024RMB'000 | - | 87,000 | PDF p. 153 |
| Denominated in RMB at fixed rate of 3.00% per annum as at 31 December 2025RMB'000 | 7,033 | - | PDF p. 153 |
| TotalRMB'000 | 651,815 | 831,300 | PDF p. 153 |
The ranges of effective interest rates (which are also equal to contractual interest rate) on the Group’s borrowings and their carrying values are as follows. Quotes for rows with wrapped labels use the continuation line containing the values.
| Item / unit | 2025RMB'000 | 2024RMB'000 | Source |
|---|---|---|---|
| Lease liabilities payable | |||
| Within one yearRMB'000 | 16,597 | 16,933 | PDF p. 152 |
| Within a period of more than one year but not more than two yearsRMB'000 | 10,743 | 7,192 | PDF p. 152 |
| Within a period of more than two years but not more than five yearsRMB'000 | 10,924 | 5,318 | PDF p. 152 |
| Less: Amount due for settlement with 12 months shown under current liabilitiesRMB'000 | (16,597) | (16,933) | PDF p. 152 |
| Amount due for settlement after 12 months shown under non-current liabilitiesRMB'000 | 21,667 | 12,510 | PDF p. 152 |
The weighted average incremental borrowing rate applied to lease liabilities is 4.75% for both years.
Total lease liabilities payable of 38,264 (2025) and 29,443 (2024) are printed as an unlabelled subtotal line.
Payout
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Dividend Policy | The Board has adopted a dividend policy (the “Dividend Policy”). Under the Dividend Policy, the Company does not have any pre-determined dividend payout ratio. Although the Company intends to declare and pay dividends in the future, the declaration, payment and amount of any dividends are subject to the Board’s discretion having regard to the following factors: (a) the Group’s actual and expected financial performance; (b) the Group’s expected working capital requirements and future development plans; (c) the Group’s liquidity position; (d) the economic outlook; (e) contractual restrictions or obligations; (f) shareholders’ interests; and (g) any other factors the Board may consider relevant. | Company | PDF p. 50 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| 2025 Interim - RMB0.1555 (2024: 2024 Interim dividend | RMB0.1555 | 2025 interim dividend per share, paid during 2025 | PDF p. 125 |
| RMB0.1507) per share | RMB0.1507 | 2024 interim dividend per share (comparative) | PDF p. 125 |
| 2025 final - RMB 0.1366 (2024: 2024 final | RMB 0.1366 | 2025 proposed final dividend per share | PDF p. 125 |
| 2024 Final - RMB0.1174 (2024: 2023 final dividend | RMB0.1174 | 2024 final dividend per share (comparative), paid during 2025 | PDF p. 125 |
| Final Dividend | RMB0.1366 (equivalent to HKD0.155 and SGD0.025) per ordinary Share | 2025 final dividend | PDF p. 49 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| total dividend for the year ended 31 December 2025 | RMB0.2921 per share | Total dividend for 2025 (interim + proposed final); 2024 total RMB0.2681 per share, increase of 9.0% | PDF p. 4 |
| total dividend of RMB0.2681 per share | RMB0.2681 per share | Total dividend for 2024 (comparative) | PDF p. 4 |
Extracted from CHINA MEDICAL SYSTEM HOLDINGS LIMITED ANNUAL REPORT 2025 and checked against the cited pages; see the original report for full context.
Auditor’s report
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Deloitte Touche Tohmatsu | Deloitte Touche Tohmatsu | Group consolidated financial statements, year ended 31 December 2025 | PDF p. 81 |
| Engagement partner | Sy, Sunnie (practising certificate number: P06034) | Group consolidated financial statements, year ended 31 December 2025 | PDF p. 81 |
| Opinion | In our opinion, the consolidated financial statements give a true and fair view | Group consolidated financial statements, year ended 31 December 2025 | PDF p. 77 |
Extracted from CHINA MEDICAL SYSTEM HOLDINGS LIMITED ANNUAL REPORT 2025 and checked against the cited pages; see the original report for full context.
Group and parent company or bank figures are labelled separately. Parentheses indicate negative amounts; a dash and NA retain the report’s notation.
Comparative figures follow CHINA MEDICAL SYSTEM HOLDINGS LIMITED ANNUAL REPORT 2025, including retrospective adjustments. Adjusted and reported earnings may have different definitions; refer to each statement’s notes.
These tables show the available extracted figures. The original annual report contains the full statements, notes and definitions.